Search results for "Leukemia"

showing 10 items of 976 documents

Bcl-xL and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells

2008

AIM: To explore the role of Bcl-x(L) and Myeloid cell leukaemia (Mcl)-1 for the apoptosis resistance of colorectal carcinoma (CRC) cells towards current treatment modalities. METHODS: Bcl-x(L) and Mcl-1 mRNA and protein expression were analyzed in CRC cell lines as well as human CRC tissue by Western blot, quantitative PCR and immunohistochemistry. Bcl-x(L) and Mcl-1 protein expression was knocked down or increased in CRC cell lines by applying specific siRNAs or expression plasmids, respectively. After modulation of protein expression, CRC cells were treated with chemotherapeutic agents, an antagonistic epidermal growth factor receptor (EGFR1) antibody, an EGFR1 tyrosine kinase inhibitor, …

Organoplatinum CompoundsCell SurvivalCellbcl-X ProteinAntineoplastic AgentsApoptosisBcl-xLAdenocarcinomaBiologyIrinotecanTNF-Related Apoptosis-Inducing LigandDownregulation and upregulationhemic and lymphatic diseasesCell Line TumormedicineHumansRNA Messengerfas ReceptorViability assayneoplasmsColorectal CancerGastroenterologyGeneral MedicineTransfectionFas receptorMolecular biologydigestive system diseasesErbB ReceptorsOxaliplatinmedicine.anatomical_structureProto-Oncogene Proteins c-bcl-2ApoptosisCell cultureCancer researchbiology.proteinMyeloid Cell Leukemia Sequence 1 ProteinCamptothecinFluorouracilColorectal NeoplasmsWorld Journal of Gastroenterology
researchProduct

Effects of E-64 (cysteine-proteinase inhibitor) and pepstatin (aspartyl-proteinase inhibitor) on metastasis formation in mice with mammary and ovaria…

1994

The effects of E-64 (Cathepsin B and L inhibitor) and Pepstatin A (Cathepsin D inhibitor) on spontaneous and experimental metastasis formation were investigated in mice with MCa mammary carcinoma, M5076 ovarian sarcoma and L1210 leukemia. Pepstatin induced a marked decrease in the number of spontaneous metastasis in MCa or M5076 tumor bearing mice. This phenomenon was also noted with E-64 but only in M5076 tumor bearing mice. On the other hand, both these agents were unable to prevent the formation of experimental metastasis in mice injected i.v. with L1210, MCa or M5076 tumor cells or with tumor cells in which Cathepsin B, L and D activities were inhibited by a 24 hour continuous exposure …

Ovarian NeoplasmsCathepsin LMammary Neoplasms ExperimentalpepstatinCysteine Proteinase Inhibitorsproteinase inhibitors.Cathepsin DCathepsinsCathepsinCathepsin BCysteine EndopeptidasesMiceLeucineEndopeptidasesPepstatinsTumor Cells CulturedAnimalsmetastasiFemaleNeoplasm MetastasisLeukemia L1210E-64In vivo (Athens, Greece)
researchProduct

Bridge-Induced Translocation between NUP145 and TOP2 Yeast Genes Models the Genetic Fusion between the Human Orthologs Associated With Acute Myeloid …

2017

In mammalian organisms liquid tumors such as acute myeloid leukemia (AML) are related to spontaneous chromosomal translocations ensuing in gene fusions. We previously developed a system named bridge-induced translocation (BIT) that allows linking together two different chromosomes exploiting the strong endogenous homologous recombination system of the yeast Saccharomyces cerevisiae. The BIT system generates a heterogeneous population of cells with different aneuploidies and severe aberrant phenotypes reminiscent of a cancerogenic transformation. In this work, thanks to a complex pop-out methodology of the marker used for the selection of translocants, we succeeded by BIT technology to preci…

P53bridge-induced translocationgene fusionnucleoporinacute myeloid leukemiayeastlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-282Frontiers in Oncology
researchProduct

PROTACs: The Future of Leukemia Therapeutics

2022

The fight to find effective, long-lasting treatments for cancer has led many researchers to consider protein degrading entities. Recent developments in PROteolysis TArgeting Chimeras (PROTACs) have signified their potential as possible cancer therapies. PROTACs are small molecule, protein degraders that function by hijacking the built-in Ubiquitin-Proteasome pathway. This review mainly focuses on the general design and functioning of PROTACs as well as current advancements in the development of PROTACs as anticancer therapies. Particular emphasis is given to PROTACs designed against various types of Leukemia/Blood malignancies.

PROTACsleukemiacanceranticancer therapeuticsCell BiologylinkerDevelopmental BiologyFrontiers in Cell and Developmental Biology
researchProduct

Wikipedia network analysis of cancer interactions and world influence

2019

AbstractWe apply the Google matrix algorithms for analysis of interactions and influence of 37 cancer types, 203 cancer drugs and 195 world countries using the network of 5 416 537 English Wikipedia articles with all their directed hyperlinks. The PageRank algorithm provides the importance order of cancers which has 60% and 70% overlaps with the top 10 cancers extracted from World Health Organization GLOBOCAN 2018 and Global Burden of Diseases Study 2017, respectively. The recently developed reduced Google matrix algorithm gives networks of interactions between cancers, drugs and countries taking into account all direct and indirect links between these selected 435 entities. These reduced n…

PageRankDatabases FactualComputer scienceSocial Sciences01 natural sciencesLung and Intrathoracic TumorsHematologic Cancers and Related Disorders0302 clinical medicineSociologyNeoplasmsBreast TumorsMedicine and Health SciencesComputingMilieux_MISCELLANEOUSNon-Hodgkin lymphoma0303 health sciencesMultidisciplinaryGoogle matrixApplied MathematicsSimulation and ModelingProstate Cancer[PHYS.PHYS.PHYS-SOC-PH]Physics [physics]/Physics [physics]/Physics and Society [physics.soc-ph]QRProstate DiseasesOnline EncyclopediasHematology[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciencesOvarian CancerOncology030220 oncology & carcinogenesisPhysical SciencesMedicineLymphomasCancersAlgorithmsNetwork analysisResearch ArticleScienceUrologyMEDLINEComplex networksAntineoplastic Agents[SDV.CAN]Life Sciences [q-bio]/CancerResearch and Analysis Methods[INFO.INFO-SI]Computer Science [cs]/Social and Information Networks [cs.SI]World Wide Web03 medical and health sciences0103 physical sciencesBreast CancerLeukemiasmedicineHumansMass Media010306 general physicsPagerank algorithm030304 developmental biologyGoogle matrixCancerCancers and NeoplasmsHyperlinkmedicine.diseaseData scienceCommunicationsGenitourinary Tract TumorsCancer drugsRankingEncyclopedias[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie[INFO.INFO-BI]Computer Science [cs]/Bioinformatics [q-bio.QM]Gynecological TumorsMathematicsWikipedia
researchProduct

Parathyroid hormone-related protein (PTHrP)-dependent modulation of gene expression signatures in cancer cells

2022

PTHrP is encoded by PTHLH gene which can generate by alternative promoter usage and splicing mechanisms at least three mature peptides of 139, 141 and 173 amino acids with distinct carboxy terminus. PTHrP may undergo proteolytic processing into smaller bioactive forms, comprising an amino terminus peptide, which is the mediator of the "classical" PTH-like effect, as well as midregion and carboxy terminus peptides that act as multifaceted critical regulator of proliferation, differentiation and apoptosis via the reprogramming of gene expression in normal and neoplastic cells. Moreover, a nuclear/nucleolar localization signal sequence is present in the [87-107] domain allowing PTHrP nuclear i…

Parathyroid HormoneNeoplasmsParathyroid Hormone-Related ProteinHumansApoptosisSettore BIO/06 - Anatomia Comparata E CitologiaPeptidesTranscriptomeGene signatures Bone tumor Breast tumor Gastrointestinal tumor Prostate tumor Lung cancer Leukemia/lymphoma
researchProduct

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

2017

Abstract The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults, published in 2010, has found broad acceptance by physicians and investigators caring for patients with AML. Recent advances, for example, in the discovery of the genomic landscape of the disease, in the development of assays for genetic testing and for detecting minimal residual disease (MRD), as well as in the development of novel antileukemic agents, prompted an international panel to provide updated evidence- and expert opinion-based recommendations. The recommendations include a revised version of the ELN genetic categories, a proposal for …

PathologyNeoplasm ResidualInternational CooperationDiseaseReview ArticleBiochemistryEuropean LeukemiaNet0302 clinical medicineRisk Factorshemic and lymphatic diseasesCONVENTIONAL CARE REGIMENSDisease management (health)medicine.diagnostic_testACUTE MYELOGENOUS LEUKEMIAHematopoietic Stem Cell TransplantationDisease ManagementSINGLE CEBPA MUTATIONSHematology1ST COMPLETE REMISSIONHIGH-DOSE CYTARABINELeukemia Myeloid AcuteTreatment Outcome030220 oncology & carcinogenesisPractice Guidelines as TopicAdultmedicine.medical_specialtyConsensusImmunologyBUSULFAN PLUS CYCLOPHOSPHAMIDEMEDLINEMINIMAL RESIDUAL DISEASEAntineoplastic AgentsACUTE MYELOID-LEUKEMIAEnasidenibTransplantation AutologousDrug Administration ScheduleImmunophenotyping03 medical and health sciencesmedicineHumansGenetic TestingIntensive care medicineGenetic testingbusiness.industrySTEM-CELL TRANSPLANTATIONCell BiologyRANDOMIZED PHASE-IIIMinimal residual diseaseTransplantationbusinessSettore MED/15 - Malattie del Sangue030215 immunology
researchProduct

Transfusion-associated graft-versus-host disease-report of two further cases with an immunohistochemical analysis

1994

Summary Transfusion-associated graft-vs.-host disease (tGVHD) is a severe disease usually affecting immunocompromised hosts with haematological neoplasia. Two patients with acute leukaemia are reported, who developed fatal tGVHD after blood transfusions. Intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1) and endothelial leucocyte adhesion molecule 1 (ELAM-1) expression and the CD4/CD8 ratio were assessed in lesional skin. ICAM-1 was strongly expressed on epidermal keratinocytes and endothelial cells (EC) and correlated with HLA-DR staining. VCAM-1 was strongly expressed on EC in the superficial dermal vessels. ELAM-1 stained weakly on EC in some of the su…

Pathologymedicine.medical_specialtyBlood transfusionCD3medicine.medical_treatmentIntercellular Adhesion Molecule-1CD4-CD8 RatioGraft vs Host DiseaseVascular Cell Adhesion Molecule-1CD18DermatologyTransfusion-associated graft versus host diseaseFatal OutcomeHumansLeukemia-Lymphoma Adult T-CellMedicineSkinbiologybusiness.industryCell adhesion moleculeTransfusion ReactionMiddle AgedIntercellular Adhesion Molecule-1medicine.diseaseLeukemia Myeloid AcuteLeukemiaImmunologybiology.proteinFemalebusinessCell Adhesion MoleculesCD8Clinical and Experimental Dermatology
researchProduct

Exploratory study on the effects of biodegradable nanoparticles with drugs on malignant B cells and on a human/mouse model of Burkitt lymphoma.

2010

The aim of this study was to determine if Rituximab coated Biodegradable Nanoparticles (BNPs) loaded with Chlorambucil and Hydroxychloroquine could induce apoptosis of B-Chronic Lymphocytic Leukemia (B-CLL), MEC-1 and BJAB cells in vitro and evaluate their toxic and therapeutic effects on a Human/Mouse Model of Burkitt Lymphoma at an exploratory, proof of concept scale. We found that Rituximab-Chlorambucil-Hydroxychloroquine BNPs induce a decrease in cell viability of malignant B cells in a dose-dependent manner. The mediated cytotoxicity resulted from apoptosis, and was confirmed by monitoring the B-CLL cells after Annexin V/propidium iodide staining. Additional data revealed that these BN…

Pathologymedicine.medical_specialtyCell Survivalhuman/mouse model of Burkitt lymphoma.human lymphomamodel SCID mouseAntineoplastic Agentschemistry.chemical_compoundAntibodies Monoclonal Murine-DerivedMicerituximabimmune system diseasesAnnexinhemic and lymphatic diseasesnanoparticles; rituximab; human lymphoma; model SCID mouseTumor Cells CulturedMedicineAnimalsHumansPharmacology (medical)Propidium iodideGeneral Pharmacology Toxicology and PharmaceuticsCytotoxicityB-LymphocytesChlorambucilDose-Response Relationship Drugbusiness.industrymalignant B cellnanoparticleDrug SynergismGeneral MedicineBiodegradable nanoparticles with drugmedicine.diseaseBurkitt LymphomaLymphomaMice Inbred C57BLLeukemiaDisease Models AnimalDrug CombinationschemistryApoptosisMonoclonalCancer researchNanoparticlesChlorambucilbusinessRituximabmedicine.drugHydroxychloroquine
researchProduct

Granulocytic sarcoma of the oral cavity in a chronic myeloid leukemia patient : an unusual presentation

2009

Intraoral granulocytic sarcoma is an unusual manifestation of chronic or acute leukemia. The oral manifestations often involve enlargements of the gingival and mucosal tissue from direct leukemic cell infiltration. Only 38 cases have been reported in scientific literature to date. We present the case of a 47 year-old female who was diagnosed with chronic myeloid leukemia (CML) in December 2006. She was referred to a dentist for further evaluation, revealing generalized gingival overgrowth as well as periodontal, apical disease, and bleeding of the gums. An oral biopsy was performed and histological features revealed immature blast-like cells.

Pathologymedicine.medical_specialtyDiseaseMyelogenousLeukemia Myelogenous Chronic BCR-ABL Positivehemic and lymphatic diseasesBiopsyMedicineHumansSarcoma MyeloidGeneral DentistryAcute leukemiamedicine.diagnostic_testbusiness.industryMyeloid leukemiaMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]LeukemiaOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASSurgeryFemaleMouth NeoplasmsSarcomabusinessInfiltration (medical)
researchProduct